Skip to main content

Animations

MJFF Publications

5951 - 5960 of 9038 Results
Title
Year
  • Year
  • 2024
  • 2024
  • 2024
  • 2024
  • 2024
  • 2024
  • 2024
  • 2024
  • 2024
  • 2024
  • Summary Details
    OPEN
    Title: Self-supervised learning for human activity recognition using 700,000 person-days of wearable data
    Journal Name: npj Digital Medicine
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1038/s41746-024-01062-3
    Citation Count: 119
  • Summary Details
    OPEN
    Title: α-Synuclein triggers cofilin pathology and dendritic spine impairment via a PrPC-CCR5 dependent pathway
    Journal Name: Cell Death & Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41419-024-06630-9
    Citation Count: 16
  • Summary Details
    OPEN
    Title: Resequencing the complete SNCA locus in Indian patients with Parkinson’s disease
    Journal Name: npj Parkinson's Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41531-024-00676-4
    Citation Count: 5
  • Summary Details
    OPEN
    Title: Longitudinal cognitive decline characterizes the profile of non-PD-manifest GBA1 mutation carriers
    Journal Name: npj Parkinson's Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41531-024-00706-1
    Citation Count: 7
  • Summary Details
    OPEN
    Title: Investigating alpha‐synuclein co‐pathology in Alzheimer's disease by means of cerebrospinal fluid alpha‐synuclein seed amplification assay
    Journal Name: Alzheimer's & Dementia
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/alz.13658
    Citation Count: 108
  • Summary Details
    OPEN
    Title: Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease
    Journal Name: Nature Medicine
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41591-024-02886-y
    Citation Count: 116
  • Summary Details
    OPEN
    Title: Single-cell multiplex chromatin and RNA interactions in ageing human brain
    Journal Name: Nature
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41586-024-07239-w
    Citation Count: 56
  • Summary Details
    OPEN
    Title: Predicting the occurrence of mild cognitive impairment in Parkinson’s disease using structural MRI data
    Journal Name: Frontiers in Neuroscience
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fnins.2024.1375395
    Citation Count: 12
  • Summary Details
    OPEN
    Title: Profiling Protein–Protein Interactions in the Human Brain by Refined Cofractionation Mass Spectrometry
    Journal Name: Journal of Proteome Research
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1021/acs.jproteome.3c00685
    Citation Count: 5
  • Summary Details
    OPEN
    Title: Expanding the phenotype of PPP1R21‐related neurodevelopmental disorder
    Journal Name: Clinical Genetics
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1111/cge.14492
    Citation Count: 6
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.